ADOC.PA
Strong SellSinkerAdocia SA · Healthcare · France · $94M · Avg Vol: $337K/d
Sinker: Weak, expensive and falling. Nothing here to keep it afloat.
ABOUT ADOCIA SA
Read
Adocia SA is a clinical-stage biotechnology company specializing in the development of innovative formulations of approved therapeutic proteins, with a primary focus on insulin and other hormones for diabetes treatment. The company's competitive moat is derived from its proprietary BioChaperone technology platform, which enhances the delivery and efficacy of existing biologics. It operates as a specialized niche developer partnering with major global pharmaceutical companies.
FINANCIAL SUMMARY (EUR)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 11.4M | 2.1M | 9.3M | 1.5M | -49.5% | 3.8M | 1.0M | 32.3M | 367.6% |
| EPS (EUR) | -0.39 | -1.90 | -0.60 | -0.90 | — | -0.86 | -0.49 | -7.10 | — |
| Shares | 20.0M | 14.1M | 15.6M | 19.6M | -2.1% | 20.2M | — | — | — |
| Debt | 33.2M | 13.1M | 11.8M | 8.9M | -35.5% | 8.9M | — | — | — |
| Equity | -13.0M | -6.9M | -3.1M | 1.5M | — | — | — | — | — |
| Op CF | -15.0M | -5.0M | -15.6M | -6.5M | — | -6.5M | — | — | — |
| Inv CF | 21.9M | -0.1M | -0.3M | -0.3M | — | — | — | — | — |
| Fin CF | -4.6M | 0.6M | 10.4M | 16.5M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of ADOC.PA are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| ADOC.PA | Adocia SA(you) | $94M | 0 | Strong Sell |
| ABNX.PA | ABIONYX Pharma SA | $100M | 1 | Strong Sell |
| OSE.PA | OSE Immunotherapeutics SA | $89M | 4 | Strong Sell |
| ALSEN.PA | Sensorion SA | $162M | 3 | Strong Sell |
| ALTHX.PA | THX Pharma Société Anonyme | $71M | 9 | Strong Sell |
| ALGAE.PA | Fermentalg SA | $64M | 21 | Sell |
| ALCLS.PA | Cellectis S.A. | $355M | 5 | Strong Sell |
| IPHA | Innate Pharma S.A. | $248M | 16 | Strong Sell |
| TNG.PA | Transgene SA | $259M | 18 | Strong Sell |
| VLA.PA | Valneva SE | $614M | 3 | Strong Sell |
Peer medians: ROE -33.6% · P/E 22.9x · Gross margin 73.0%
Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.